Fenofibrate and Metformin Insulin Sensitivity in Type 2 Diabetics Study

• Status: Terminated
• Trial end date: 2007-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Double-blind, randomized placebo-controlled study in type 2 diabetes and dyslipidemic patients.Patients will be randomized to one of four treatment arms for 16 weeks: placebo, fenofibrate, metformin, or metformin and fenofibrate combination.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Solvay Pharmaceuticals
• Treatments: Fenofibrate; Insulin; Metformin

Criteria

Inclusion Criteria:

• Patients with type 2 diabetes mellitus and dyslipidemia.

Exclusion Criteria:

• Type 1 diabetes.